Allergy Therapeutics - Positive top line phase I results for Acarovac MPL
- Investigational house dust mite allergy vaccine demonstrates good safety and tolerability profile
- Patients experienced symptom improvement in response to Nasal Provocation Testing
The primary endpoint was the safety and tolerability of 7 injections of Acarovac MPL administered over 6-12 weeks each 1-2 weeks apart. The formulation was well tolerated. The safety profile was satisfactory and the reported adverse events were consistent with what have been observed with similar formulations of allergy vaccines.
Secondary endpoints included the effect of treatment on response to nasal provocation test (NPT), immunological parameters including immunoglobulins and patients' satisfaction with the treatment. A significant improvement from baseline in patients' total symptom scores following NPT after 12 weeks, and significant increases in immunoglobulin markers and reduction in IL-4 were observed. Patients reported high satisfaction with their treatment measured via the ESPIA questionnaire (Satisfaction Scale for Patients Receiving Allergen Immunotherapy).
Acarovac MPL is a subcutaneous immunotherapy product containing Dermatophagoides pteronyssinus and Dermatophagoides farinae allergoids adsorbed to the adjuvant system comprised of MCT® (Microcrystalline Tyrosine) and MPL.
- ENDS -
For further information, please contact:
+44 (0) 1903 845 820
Nick Wykeman, Chief Financial Officer
+44 (0) 20 7886 2500
+44 20 3709 5700
Stern Investor Relations, Inc.
+1 212 362 1200
Notes for editors:
About Acarovac MPL
House dust mite is the major cause of perennial allergic rhinitis and allergic asthma. Acarovac MPL builds on the strong foundation of technologies employed in the successful Pollinex Quattro range of allergy immunotherapies. It is the only house-dust mite immunotherapy utilising the adjuvant system comprised of MCT® (Microcrystalline Tyrosine), a natural, biodegradable depot, and the adjuvant MPL for the treatment of perennial allergic rhinitis which makes this vaccine unique in the
Formed in 1999 out of
 Calderón M et al., Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015 Jul;136(1):38-48
 QYR Pharma report.
This information is provided by RNS, the news service of the
Quick facts: Allergy Therapeutics PLC
Market Cap: £90.81 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE